Investigating SCAMP3's role in aggressive breast cancer
SCAMP3 as a regulator of EGFR/STAT3 axis in triple-negative breast cancer
This study is looking at a protein called SCAMP3 that is found in higher amounts in triple-negative breast cancer, to see how it affects the growth of the cancer and to find new ways to treat patients with this type of breast cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Universidad Central Del Caribe NIH-funded |
| Lab location | 1 site (Bayamon, United States) |
| Project ID | NIH-10643857 on NIH RePORTER |
What this research studies
This research focuses on understanding how SCAMP3, a protein found to be overexpressed in triple-negative breast cancer (TNBC), contributes to the disease's progression. By examining the molecular mechanisms behind SCAMP3's regulation of the epidermal growth factor receptor (EGFR) and its interaction with other signaling proteins, the study aims to identify potential new therapeutic targets. The approach involves detailed biological analyses to uncover how SCAMP3 influences cancer cell behavior, which could lead to improved treatment options for patients with TNBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer who may benefit from novel treatment strategies.
Not a fit: Patients with other types of breast cancer or those whose cancer is not triple-negative may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new therapies that significantly improve survival rates for patients with triple-negative breast cancer.
How similar studies have performed: While the specific role of SCAMP3 in TNBC is still being explored, similar research on molecular drivers in other cancers has shown promising results, indicating potential for success in this area.
Where this research is happening
Bayamon, United States
- Universidad Central Del Caribe — Bayamon, United States (Active)
Researchers
- Principal investigator: Suarez, Ivette — Universidad Central Del Caribe
- Study coordinator: Suarez, Ivette
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.